Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Int Arch Allergy Immunol. 2022;183(9):939-945. doi: 10.1159/000524612. Epub 2022 May 6.
The effectiveness of glucocorticoids in preventing biphasic reactions in patients with anaphylaxis remains controversial.
We evaluated the effects of glucocorticoids on rates of biphasic reactions in hospitalized patients with anaphylaxis treated with adrenaline.
In this retrospective observational study using a national inpatient database in Japan, we identified 31,570 hospitalized patients with anaphylaxis treated with adrenaline on the day of admission. We divided them into two groups: those who were treated with adrenaline plus glucocorticoids and those who received adrenaline only on the day of admission. The primary outcome was the occurrence of a biphasic reaction, defined as requiring two or more ampules of adrenaline within 7 days of admission. We performed a one-to-four propensity score matching analysis to compare the outcomes between the two groups.
Of the 31,570 eligible patients, 28,145 (89.2%) were treated with glucocorticoids on the day of admission. The overall percentage of biphasic reactions within 7 days of admission was 11.2%. One-to-four propensity score matching created matched cohorts of 3,425 patients in the control group and 13,700 patients in the glucocorticoid group. After propensity score matching, there were no significant differences in rates of biphasic reactions (10.7% in the glucocorticoids group vs. 10.5% in the control group; odds ratio, 1.03; 95% confidence interval, 0.85-1.24; p = 0.77) between patients with anaphylaxis treated with and without glucocorticoids on the day of admission.
Our findings do not support the use of glucocorticoids to prevent biphasic reactions in hospitalized patients with severe anaphylaxis requiring adrenaline.
糖皮质激素在预防过敏反应患者双相反应中的有效性仍存在争议。
我们评估了糖皮质激素对接受肾上腺素治疗的住院过敏反应患者双相反应发生率的影响。
本回顾性观察性研究使用了日本全国住院患者数据库,共纳入 31570 例因过敏反应而在入院当天接受肾上腺素治疗的住院患者。我们将其分为两组:一组在入院当天接受肾上腺素加糖皮质激素治疗,另一组仅在入院当天接受肾上腺素治疗。主要结局为双相反应的发生,定义为在入院后 7 天内需要使用 2 支或以上肾上腺素。我们进行了 1:4 倾向评分匹配分析,以比较两组之间的结局。
在 31570 例合格患者中,28145 例(89.2%)在入院当天接受了糖皮质激素治疗。入院后 7 天内双相反应的总发生率为 11.2%。1:4 倾向评分匹配后,对照组有 3425 例患者和糖皮质激素组有 13700 例患者匹配。倾向评分匹配后,两组双相反应发生率无显著差异(糖皮质激素组为 10.7%,对照组为 10.5%;优势比,1.03;95%置信区间,0.85-1.24;p = 0.77)。
我们的研究结果不支持在需要肾上腺素治疗的严重过敏反应住院患者中使用糖皮质激素预防双相反应。